Resources Repository
-
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Europe | Mental Health | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Chronic Disease/Risk | Health Systems | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Europe | Infectious Diseases | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | Value of Information | State-Transition | Decision Analysis | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Global | North America | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
Resource PackWeb Portal, Teaching Resource 2018Resource Pack: Mental Health and Modeling
This resource pack, curated by the Center for Health Decision Science, features resources on modeling …
This resource pack, curated by the Center for Health Decision Science, features resources on modeling approaches applied to mental health. We aim to provide an overview of different techniques to guide researchers and practitioners in applying decision science and economic modeling to this public health challenge. More specifically, this resource pack contains review articles comparing different modeling techniques in the evaluation of treatments for depression, bipolar disorder and schizophrenia. The majority of articles in this…
Europe | Mental Health | Costing Methods | Health Outcomes | Evidence Synthesis | Mathematical Models | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Middle East & North Africa | Infectious Diseases | Decision Theory | Costing Methods | Health Outcomes | State-Transition | Decision Analysis | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Middle East & North Africa | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Child/Nutrition | Global Governance | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Asia & Pacific -
Resource PackPublication, Teaching Resource 2017Resource Pack: CEA Herpes Zoster Vaccine
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. …
This resource pack on the cost-effectiveness of herpes zoster vaccination was curated to support Dr. Lisa Prosser's seminar on November 9, 2017 at the Center for Health Decision Science. Dr. Prosser discussed an economic evaluation of vaccination against herpes zoster. Herpes zoster—more commonly known as shingles—presents a major burden for older Americans but, until recently, the only available vaccine (Zoster Vaccine Live, ZVL) was relatively ineffective past 10 years. A recently approved vaccine–herpes zoster subunit…
Europe | Infectious Diseases | Preferences/Values | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Clinical Care | Culture/Society | Health/Medicine | Science/Technology | North America -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Middle East & North Africa | Infectious Diseases | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2008Economic Burden of Personality Disorders in Mental Health Care
This paper aimed to investigate the economic burden of patients with personality disorders in mental …
This paper aimed to investigate the economic burden of patients with personality disorders in mental health care. The direct and indirect costs were assessed for 1740 study participants with a clinical diagnosis of personality disorders using the Trimbos and Institute for Medical Technology Assessment Questionnaire on Costs Associated with Psychiatric Illness. Results indicated that the mean total costs in the 12 months prior to treatment were €11,126 per patient. Two thirds (66.5%) of these costs consisted…
Europe | Mental Health | Costing Methods | Evidence Synthesis | Health/Medicine -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
Europe | Infectious Diseases | Value of Information | State-Transition | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | North America